{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:00:11Z","timestamp":1758052811058,"version":"3.44.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.clinbiochem.2014.01.009","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T03:45:58Z","timestamp":1390448758000},"page":"478-480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Validation of interleukin 28B genotyping assay for clinical use"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5116-3780","authenticated-orcid":false,"given":"Mark A.","family":"Cervinski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soya S.","family":"Sam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather B.","family":"Steinmetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-5036","authenticated-orcid":false,"given":"Brendan","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Tsongalis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"World Heath Organization","key":"10.1016\/j.clinbiochem.2014.01.009_bb0005"},{"author":"Centers for Disease Control and Prevention","key":"10.1016\/j.clinbiochem.2014.01.009_bb0010"},{"key":"10.1016\/j.clinbiochem.2014.01.009_bb0015","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2014.01.009_bb0020","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/hep.1840220406","article-title":"Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C","volume":"22","author":"Martinot-Peignoux","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.clinbiochem.2014.01.009_bb0025","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1440-1746.1993.tb01648.x","article-title":"Factors useful in predicting the response to interferon therapy in chronic hepatitis C","volume":"8","author":"Tsubota","year":"1993","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinbiochem.2014.01.009_bb0030","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1478-3231.2009.02188.x","article-title":"The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report","volume":"30","author":"Antaki","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.clinbiochem.2014.01.009_bb0035","doi-asserted-by":"crossref","first-page":"e18322","DOI":"10.1371\/journal.pone.0018322","article-title":"IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection","volume":"6","author":"Lin","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2014.01.009_bb0040","doi-asserted-by":"crossref","first-page":"e17232","DOI":"10.1371\/journal.pone.0017232","article-title":"Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms","volume":"6","author":"Lagging","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2014.01.009_bb0045","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinbiochem.2014.01.009_bb0050","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jhep.2011.09.008","article-title":"IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C","volume":"56","author":"Asselah","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinbiochem.2014.01.009_bb0055","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.gastro.2010.05.079","article-title":"An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response","volume":"139","author":"Mangia","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinbiochem.2014.01.009_bb0060","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S0168-8278(12)61106-4","article-title":"100% SVR in IL28B patients treated with 12weeks of Telaprevir, Peginterferon and Ribavirin in the PROVE2 trial","volume":"56","author":"Bronowicki","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinbiochem.2014.01.009_bb0065","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(11)60015-9","article-title":"Similar SVR rates in IL28B CC, CT or TT prior relapser, partial- or null-responder patients treated with Telaprevir\/Peginterferon\/Ribavirin: retrospective analysis of the REALIZE study","volume":"54","author":"Pol","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinbiochem.2014.01.009_bb0070","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study","volume":"138","author":"Rauch","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinbiochem.2014.01.009_bb0075","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/jmv.22092","article-title":"Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity\/resistance in patients with chronic hepatitis C","volume":"83","author":"Toyoda","year":"2011","journal-title":"J Med Virol"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912014000125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912014000125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:44:46Z","timestamp":1757864686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912014000125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0009912014000125"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2014.01.009","relation":{},"ISSN":["0009-9120"],"issn-type":[{"type":"print","value":"0009-9120"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of interleukin 28B genotyping assay for clinical use","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2014.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}